Related Experiment Video

Updated: May 7, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib

Masafumi Koshiyama1, Noriomi Matsumura1, Tsukasa Baba1

  • 1Department of Gynecology and Obstetrics; Kyoto University Graduate School of Medicine; Kyoto, Japan.

Cancer Biology & Therapy
|October 8, 2013
PubMed

Insights

Sorafenib shows promise in treating chemoresistant ovarian clear cell carcinoma (OCCC). This oral multikinase inhibitor demonstrated good efficacy and safety in two patients with recurrent OCCC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ovarian clear cell carcinoma (OCCC) is a chemoresistant subtype of ovarian cancer.
  • OCCC shares cellular and gene expression similarities with renal cell carcinoma (RCC).
  • Sorafenib is an oral multikinase inhibitor effective in RCC treatment.

Observation:

  • The efficacy of sorafenib in OCCC was previously unknown.
  • Two patients with recurrent, chemoresistant OCCC were treated with sorafenib.
  • Both patients exhibited a positive response to sorafenib without severe adverse effects.

Findings:

  • Sorafenib demonstrated good effect in patients with recurrent chemoresistant OCCC.
  • The treatment was well-tolerated, with no severe side effects observed.

Implications:

  • Sorafenib may be a valuable therapeutic option for chemoresistant OCCC.
  • Further investigation into sorafenib for OCCC treatment is warranted.
Keywords:
ovarian clear cell carcinomaprogression-free survivalsorafenib

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...